<SEC-DOCUMENT>0000105770-14-000060.txt : 20141016
<SEC-HEADER>0000105770-14-000060.hdr.sgml : 20141016
<ACCEPTANCE-DATETIME>20141015091404
ACCESSION NUMBER:		0000105770-14-000060
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20141014
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141015
DATE AS OF CHANGE:		20141015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			WEST PHARMACEUTICAL SERVICES INC
		CENTRAL INDEX KEY:			0000105770
		STANDARD INDUSTRIAL CLASSIFICATION:	FABRICATED RUBBER PRODUCTS, NEC [3060]
		IRS NUMBER:				231210010
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-08036
		FILM NUMBER:		141156608

	BUSINESS ADDRESS:	
		STREET 1:		101 GORDON DR
		STREET 2:		P O BOX 645
		CITY:			LIONVILLE
		STATE:			PA
		ZIP:			19341-0645
		BUSINESS PHONE:		6105942900

	MAIL ADDRESS:	
		STREET 1:		101 GORDON DRIVE
		STREET 2:		PO BOX 645
		CITY:			LIONVILLE
		STATE:			PA
		ZIP:			19341-0645

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WEST CO INC
		DATE OF NAME CHANGE:	19990405
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8koct152014.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>Form 8K Oct 15 2014</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sF86DD0291CEFB4BC3E9210E8F4F2D543"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:4px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Report (Date of Earliest Event Reported) &#8211; October 14, 2014 </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><img src="westlogo10152014.jpg" style="height:101px;width:252px;"></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WEST PHARMACEUTICAL SERVICES, INC.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="33.0078125%"></td><td width="3.90625%"></td><td width="27.1484375%"></td><td width="3.90625%"></td><td width="32.03125%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pennsylvania</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1-8036</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23-1210010</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Incorporation)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">530 Herman O. West Drive, Exton, PA</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19341-0645</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Registrant&#8217;s telephone number, including area code: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">610-594-2900</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former name or address, if changed since last report)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="4.8828125%"></td><td width="95.1171875%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="4.8828125%"></td><td width="95.1171875%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="4.8828125%"></td><td width="95.1171875%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="4.8828125%"></td><td width="95.1171875%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s94510080851B6E81D36010E8F52152C4"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02 Results of Operations and Financial Condition. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 15, 2014, West Pharmaceutical Services, Inc. issued a press release pre-announcing its expected third-quarter 2014 earnings per diluted share and narrowing its adjusted earnings-per-share guidance for full year 2014. The press release is attached hereto as Exhibit 99 and incorporated herein by reference. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 14, 2014, Donald E. Morel, Jr., Ph.D., Chairman of the Board and Chief Executive Officer, announced his intention to retire at the Company's Annual Meeting in May 2015. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01 Regulation FD Disclosure.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information set forth in "Item 2.02 Results of Operations and Financial Condition," including the exhibit referred to therein, is incorporated herein by reference.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in Item 2.02 and Item 7.01 of this report (including Exhibit 99) is being furnished and is not deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (Exchange Act) or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.15625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="10.321100917431195%"></td><td width="14.449541284403669%"></td><td width="75.22935779816514%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">West Pharmaceutical Services, Inc. Press Release, dated October 15, 2014.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB5195573B9081A12744F10E8F540A341"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="44.53125%"></td><td width="40.8203125%"></td><td width="14.6484375%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WEST PHARMACEUTICAL SERVICES, INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ John R. Gailey III</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John R. Gailey III</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and General Counsel</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 15, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s057C6950AD76D2D8B95B10E8F57FD7B0"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="12.00787401574803%"></td><td width="87.99212598425197%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">West Pharmaceutical Services, Inc. Press Release, dated October 15, 2014.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exh99pressreleaseoct152014.htm
<DESCRIPTION>EXHIBIT 99 PRESS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2014 Workiva -->
		<title>Exh 99 Press Release Oct 15 2014</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s6FD02305BCE90DB010E610E8F2E06107"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 99</font></div><div style="line-height:120%;text-align:left;"><img src="exh99logo10152014.jpg" style="height:85px;width:150px;"></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.93162393162393%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="47.94816414686826%"></td><td width="52.05183585313174%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">West Contacts:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Investors:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Media:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Michael A. Anderson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Emily Denney</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Vice President and Treasurer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Global Communications</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(610) 594-3345</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(610) 594-3035</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">West Pharmaceutical Services Announces CEO Retirement and Succession Plan</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Chairman and CEO Donald E. Morel, Jr. to Retire at 2015 Annual Meeting</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Company Commences Search for Successor; Updates 2014 Outlook</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exton, PA - October 15, 2014 - West Pharmaceutical Services, Inc. [NYSE: WST], a global leader in innovative drug packaging and administration systems, said today that Donald E. Morel, Jr., Ph.D., Chairman of the Board and Chief Executive Officer, has announced his intention to retire at the Company&#8217;s Annual Meeting in May 2015.  The West Board of Directors has retained Russell Reynolds Associates, a leading executive search firm, to launch a comprehensive search to identify Dr. Morel&#8217;s successor.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dr. Morel said, &#8220;It has been a privilege to lead West these past 12 years.  My time at West has been extremely rewarding on both a personal and professional level. When I step down next May, I will sincerely miss my West colleagues around the world that have worked so diligently to contribute to our Company&#8217;s success. With our Company in a very strong financial position and poised for a bright future, the time is right for me to step back, focus on my family and pursue my philanthropic goals.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dr. Morel continued, &#8220;I am confident that the Board of Directors will identify an outstanding candidate to lead West into the next stage of its growth.  Until that time, I will continue to work with the West team to deliver value to our customers and with the Board to make the transition to new leadership a seamless process.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patrick J. Zenner, West&#8217;s Chairman, Independent Directors, said, &#8220;Don has been a strong and effective leader since joining West in 1992, rising to become Chief Executive Officer in 2002 and Chairman and CEO in 2003.  During his leadership, revenues more than tripled with the launch of many innovative products, and the stock price increased more than sixfold.  Don&#8217;s vision has positioned the Company for a bright future with a broad range of new product opportunities combined with a very strong financial position.  We are grateful for his hard work and look forward to his continuing contribution as we conduct the search for his successor.&#8221;</font></div><br><div></div><hr style="page-break-after:always"><a name="s6FD02305BCE90DB010E610E8F2E06107"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Zenner continued, &#8220;Succession planning has always been a top priority for our Board of Directors. We have confidence in Don and his current management team, the strategy we have crafted together and in our ability to conduct a thorough and careful search to identify the right person who will continue to drive growth and shareholder-value creation well into the future.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2014 Outlook</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">West plans to announce its third-quarter 2014 results on October 30, 2014.  The Company expects third-quarter U.S. GAAP earnings to be $0.43 per diluted share, including a $0.01 per-share charge for in-process research.  The Company also narrowed its adjusted earnings-per-share guidance for full-year 2014 to a range of between $1.77 and $1.82, primarily as a result of foreign currency translation from the strengthening of the dollar ($0.04 per diluted share) and tax-rate changes attributed to the geographic mix of our earnings.  &#8220;We look forward to providing additional information about our third-quarter results and full-year outlook, 2015 revenue-growth expectations, as well as our 5-year financial goals, during our earnings call,&#8221; Dr. Morel said. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About West</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">West works side-by-side with its healthcare partners from concept to the patient, designing and manufacturing packaging, diagnostic and delivery systems that promote the efficiency, reliability and safety of their products.  Every day, West is leading the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched and growing knowledge base of relevant pharmaceutical product testing, development and packaging.  Based in Exton, Pa., West supports its customers from sales, manufacturing, customer support and research and development locations in North and South America, Europe, Asia and Australia.  Established in 1923, West had 2013 sales totaling approximately $1.4 billion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward-Looking Statements </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This press release contains forward-looking statements within the meaning of the federal securities laws which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; or &#8220;potential&#8221; or the negative of these words and phrases or similar words or phrases, which are predictions of or indicate future events or trends and which do not relate solely to historical matters. While forward-looking statements reflect West&#8217;s good faith beliefs, assumptions and expectations, they are not guarantees of future performance. Furthermore, except as required by law, West disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions, new information or other changes. Known material risks, uncertainties and other factors that can affect future results are discussed or incorporated by reference in periodic reports under the </font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s6FD02305BCE90DB010E610E8F2E06107"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Securities Exchange Act of 1934, as amended, filed by West from time to time with the Securities and Exchange Commission.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WEST PHARMACEUTICAL SERVICES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#32;(in millions, except per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.64957264957265%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="51.203501094091905%"></td><td width="26.477024070021884%"></td><td width="22.319474835886215%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Current 2014</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Estimated Guidance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Prior</font></div><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Guidance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Full-Year diluted EPS - GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1.76 to $1.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1.77 to $1.89</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In-process R&amp;D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$(0.01)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">N/A</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Full-Year diluted EPS - Adjusted Non-GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1.77 to $1.82</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">$1.77 to $1.89</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The principal currency assumption used in preparing our current guidance is the translation of the euro at $1.27 for the remainder of 2014; our prior guidance assumed a $1.37 per euro translation rate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.94017094017094%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="48.99777282850779%"></td><td width="12.91759465478842%"></td><td width="14.03118040089087%"></td><td width="12.026726057906458%"></td><td width="12.026726057906458%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Three-months ending September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Operating profit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Net income</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Diluted EPS</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Reported (GAAP)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$44.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$11.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$31.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$0.43</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In-process R&amp;D</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$0.01</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Adjusted (Non-GAAP)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$45.2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$12.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$31.8</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$0.44</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Please refer to the &#8220;Non-GAAP Financial Measures&#8221; for more information.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Non-GAAP Financial Measures</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This press release and the preceding discussion of our results, financial guidance and the accompanying financial tables use the following financial measures that have not been calculated in accordance with generally accepted accounting principles (GAAP) accepted in the U.S., and therefore are referred to as non-GAAP financial measures:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Adjusted operating profit</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Adjusted net income</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Adjusted diluted EPS</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s6FD02305BCE90DB010E610E8F2E06107"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">West believes that these non-GAAP measures of financial results provide useful information to management and investors regarding business trends, results of operations, and the Company&#8217;s overall performance and financial position. Our executive management team uses these financial measures to evaluate the performance of the Company in terms of profitability and efficiency, to compare operating results to prior periods, to evaluate changes in the operating results of each segment, and to measure and allocate financial resources to our segments. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in comparing its financial measures with other companies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Our executive management does not consider such non-GAAP measures in isolation or as an alternative to such measures determined in accordance with GAAP. The principal limitation of these financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. In order to compensate for these limitations, non-GAAP financial measures are presented in connection with GAAP results. We urge investors and potential investors to review the reconciliations of our non-GAAP financial measures to the comparable GAAP financial measures, and not to rely on any single financial measure to evaluate the Company&#8217;s business.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In calculating adjusted operating profit, adjusted net income and adjusted diluted EPS, we exclude the impact of items that are not considered representative of ongoing operations. Such items may include restructuring and related costs, certain asset impairments, other specifically identified gains or losses, and discrete income tax items. A reconciliation of these adjusted non-GAAP measures to the comparable GAAP financial measures is included in the accompanying tables.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">###</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exh99logo10152014.jpg
<TEXT>
begin 644 exh99logo10152014.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!<`*(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BO._%'C
MO5-(\0W-E:+;&&+;C>A)Y`)[^]7/!7BW4_$.JS07@@$44._]VA!SD`=_K6CI
M24>8CVBO8[BBN"\8>.;W1M;^PZ<("L<8,AD4D[CSCKZ8H\'^,]4U[71:7:VX
MA$3.=B$'C&._O3]E+EY@]I&_*=[17$^-O&5WH&H6]I8"$NT9DD\Q2V,G`'7V
M-4O"_C/6]>UZ&S=;80X+RLL9R%'X^N!25*3CS=`]HK\IZ'12"EK,L****`"B
MBB@`HK*\2ZS_`&#HDU\$61T*JJ,<!B3BN'/Q6O`/^0;!_P!_#6D:4IJZ(E.,
M79GIM%5=-N);O3;:XG01R2QJ[(#D*2,XJU6985SOBKQ(-'MC!:/`VH2#Y%DD
M51&/[QR?R%+XJ\5V_ARU`/[V[E'[N('D#^\?0?SKRV2]T^]NI+B_AU&>:0[G
M<3+DG_OFMZ5+FU>QE4G;1'=?#[6)W-QIU_<QSS%C-$PF#EL_>''OS^-=G'=0
M32O%'*C.GWE!Y%>+V^H6.E:A;W^FV>H(T#!LRRC!]1PO0BO6M(ALYHDU&R8L
MERF\9/0'_/Z45H).X4Y75C3HI:*P-3Q+QH^_QAJ1])`/R45T?PN5(5U:]E.U
M(T0%O0<D_P`JY;Q2V_Q5JA_Z>&'Y<5JZ?=_V9\.;]E.);^Z\A?7`4;OTS^==
M\E>FH^AR1=IMG/:E>OJ6IW-Y)]Z>0O\`0$\#\L5U?PNCW>(;E_[EL?U8?X5S
M=O9?\4]>7[C@31P1_4Y8_H!^=;?@J\_LO3=>U#HT5LJK_O$G'ZXIU/@:0H?$
MFS*\5:A_:GB:^N`<IYGEI_NKP/Y5V'P\M[?2-#N];OY%ACE;8KOV1?\`$_RK
MSR"&2YGCAB!:65@BCU).*Z#QC>[+F#1+9O\`1--018'1Y,?,Q_SZT3C=*"",
MK-R9U%[\4[2.0K8V,LRC^-V"`_AR:BM_BLAD`NM,94[M'("1^!`KGO`_AR#Q
M#J<PO-_V:!`S!3C<Q/`S^=8VLVT-GK5[;6Q)AAF9$).3@&H5*G?EL4ZD[<Q[
MCIVHV^JV,=W9R"2&0<'H1Z@CL:P-<^(&F:/.UO&'N[A#AEB("J?0MZ_2N3T+
M5Y](^'FIR1,5=[D0Q'^Z649(_#-<:,9&2<$\GK40H)R=]BI5796/0O\`A:[[
M^=*&W_KMS_*ND\.>,[#Q%(8(U>"Z`W>5)CD>H/>N3O/!6GZIIMM+X6G2>3/[
MTR3=1CN.QS4GAKP-K&E^(+6\N/)2*(MN*R9/*D=/QHE&DXZ:,<743UU*OCCQ
M?#K5N=-MH9$$-P2[L1A]N0,?C7&+MWKO!*Y&X#N*U/$VD)H>M262W!N&50[N
M5QRW./\`/K1X;T0^(=86R$IB4HSLX7.`/:NB'+&%UL8RO*6NYZUX:UV+7]--
MQ;V\D$4;^4H<CG`'I]:7Q%XA@T*SRSQ&ZD!\F)WV[CZD^@K-,]G\/_"Z0/(;
MB7+&-0,-*Q.>G8#UKSJ\U2/5[^2[U&RNYYG_`+DV`!Z`;>!7)"FI2OT-Y3<5
M;J6C)JU]=O<R:U8"60Y):X7`]AQP*T[6/7ACRO$FEK_VW0_^RUDP#2#C?X>U
M-_I.3_[+6E!!HC8_XI+56_X$QK>3\OR,T:QLO$5W;/!+XFTQD<8(!4G\"!4_
MP_U:5'GTB\NX9I%8O"4DW''\0_K^)JM;6&AMC_BC=2'N8R?_`&:N6?4+;2M?
M-U8:;<P/;SDJK2D8`/W2,>G&,UFH\Z<2K\K3/:J*S;?Q!IMQ;13"ZB42('VL
MW(R,X-%<W*^QOS(\9UY_,\0ZBWK<R?\`H1IMY>;]*L+-3\D"O(W^\S?X`5%J
M+^9JEV_]Z>0_^/&I]!TXZMKMG9XRLD@W^RCD_H*]+:*;Z'%N[(Z'Q!8G2?A_
MHULPQ)/,9Y![E2?Y$"N=BO/)T"XM5/S7-PC,/]E`?ZM^E=G\59`#I<"\`"1L
M?]\@5Y[44O>A=E5-)61U7P_T];C7'OI1F"PC,I/^UCC^I_"N:N)VNKF6X<Y:
M5V<GZG->G^%-'>R\`W+!?](O89),8YP5(4?E_.O*Q]T44Y<TY,)JT4C<T?PW
MKFI6?VK3(W\EF*[EFV9(_&K)\`^(F)+6BDGDDS+S^M7XO%UI9>`$TNS:5;]E
M*-@$!<L26S]*Y[3Y-5U34(;.VO+II)F"C$K<#N>O0"B\W=[!:.BW.\M?!5Q-
MX"_LR?;#>F8W`R<@-T`)'M7GVI:/?Z1*8[^UDA.>&(RI^AZ5U7C+7-6T;719
M65]-%!%!&%`Q\W'7FF^&?&H62ZC\2W,MS`Z#RU=`XSWXQ40<TN;>Y4N5OE.-
M@N)K642V\KQ2#HR,5/Z5ZK\/_$=UK=I<07[>9-;%<28Y93GK[\5Y=?RP3ZA<
M2VL7DP/(S1Q_W5SP*]"\"64FC^%=1U692K3(7C!_NJIP?Q.:==)PN]Q4FU(X
MCQ)>?;_$FH7`.5:9@OT'`_E76?"JSW76H7A'W46)?Q.3_(5P.2WS-U/)KO/A
MOKRV\HT=;5FDN)6D,P;@`+W'X?K554U3LA4W>=V;GQ`TNXGL(]1LYS#):\2'
M=@;#W_`UQ-M>:IQL\301^S3M_A7L4T*7$#Q2J&CD4JRGN#UKQG5M.M]#UB>Q
MFTR281ME&$S?,IZ'@5C1E=<K-:JL[FU;W.LG'_%8V"_[TN?YBM.W?6SC_BL=
M,;\%-<G!)IO&[PQ<R?2>3_"M*W;26QGP5>-_P-S_`$JI1_K0E/\`K4ZAI]6M
M;62>;Q1IS)&I8X@4_P`C7*Z/IVM>)=0*?VP9+=6S/+'(2%![#(ZU);V=AXHO
MH['2=`^Q1H=T\[N04']?I7I.EZ7:Z/81VEE'LB3\V/J3W-9N7LUYE*/._(@C
M\.Z9'$B?9$;:`-S<DX[D^M%:5%8<S[FUD<*_PLM))&<ZC<98DGY%[UI^'?`U
MKX>U%KR.YEGDV%%#J!MSU/%=115NK-JS9*IQ3ND<WXE\'0^);J"::[EA\E"@
M5%!!R<YYK''PJLLC=J%P1GD;%YKO**2JS2LF#A%N[0R.-8HTCC7:B`*H'8"N
M.UKX;66H73W%E.UH\AW,FW<F?4#M7:44HS<7=#<4]SSB+X4OO_?:FNS_`&(N
M?U-=;H'A73_#R$VJ%YV&&FDY8^WL*VJ*J564M&Q*$5JC`\2>$;+Q((WF9X;B
M,;5E3T]".XKE6^%,V[Y=33;[Q'/\Z])HHC5G%63!TXO5G%Z5\--.LIEEOIGO
M&4Y"$;4_$=ZZZ>VBN+22VD0>2Z&,J./E(QBIJ*F4Y2=VQJ*6QY]-\*83(?(U
M.14[!X@2/QS6MX9\"Q>'=2:\-VUPYC*`%-H&2.?TKJZ*IU9M6;$J<4[I"5R/
MQ`TJ:XTY-0M;AH)+7_6$,0"A^GH?ZUU]1RQ)/$\4JAD=2K*>X-3&7*[E25U8
M\:M[N\497Q.(O;S)/\*O:<NO:]=?8;7Q`\ZGF1E=\*OJ3BHY_#DB>)Y=%M]-
M21L[DE:1P!&>C'G_`":],T/0[30;$6]H@!/S2/W<^M=-2I&*T.>$&WJ3:5ID
M.DV$=M"7?;RSN<LY[DFKM)2UR7OJ=(4444`%%)2T`%%%(:`"N7\;W$T$6F+%
M)=(LMXJ2+:MB1UP>![UU%9>MZ(-92V_TF6VDMI1-')&`2&`QWJH-*5V3)76A
MS6C>)[FPTV(WSM-"TMRN^9OWL10;E1_<@&MV?6[FU\/V.HS6R`S-%YZ;CB-7
M(!(^F165JOA-FTZ#2[6.6X^T78N;F\ED&5.?F)'<D9&!6UXDMYKCP_<6=I:?
M:'G7RE0,%"9Z,2>PXJY<K:L2KI&._B^^F)%E90.<3S`R2$`Q1MMS]2<^U2'Q
MG(UM=3Q6J[(DM70,QR?-QG/TS4S>#D:PL8H[R:VFM[8VSO$`?,5OO#GU/>B;
MP5;R,RPWEQ#`Z0HT2A2#Y7W221GM1>`>^7-$U:[U6YO?,MXH[:WG>!75R69E
M..1VXK(D\37%Y;ZQ%/:1)';12YC$Y29=O3<.N&[%>E=%I>EII<=RL<C/Y]P]
MP=V."QY'TK+E\'Q7%Q/+/?W,N^*6&,/@F,2=>>K>V>E).-QM2L8^JZ_>RV+P
M6:""&V^R!Y1*?,S)@X'J,<'-7K/QHUWX@6R\B/R7N'MUVL3(I7^)AC&#CUJQ
M/X-AFD<K>W$<<BPB2,!<,T6-IZ>@JS:>&ULM2-Q%>W(M_-><6H(";VZY/4CV
MIMPL*TKFW2T@I:R-!@C02&0*N\C:6QR1Z9I]%%`!1110`4444`85IJ-R&<&-
MI)99F5%9P%4+U%6K?5GNIHHXH.'0.Q+?=&<'ZUG7(-M9FYB8B6.X?:>#UZU=
MTV!8+R,*3_Q[#K[G-;.*M<XX3E=1N3ZAJ3V)SY(:,#)8N!GV`[FC4YY(XK9X
M2<O,HP#C<#VK-UD?\3%UR<20\]#C![>E:-Z@:&SSVF0U-DK%N;?,NQ`VN%8D
MS"HD+."&?"C;[TZ;6C'#%,(/W+J&RS@$Y[`=\5GW*_9[47$9/F+/(HR`1ACS
M3;V/;<&+>Q#P(23@GC^57R(R=::ZEQK^ZCO71,NIN@F"1TVYQ1::E-Y`CF4L
M)!+B3?S\I/%0W@\KSID)#K=JP^N`*=%$HBM^3P)_UHLK`IRON2_VVMM#"HCW
M`1*[;Y/FP>P]35ZTO7NKF5!#B.,[=^[J>.WXUCRIY+6(C8KY\:HYX)P/3CBM
M;3D"37F,\S?T%3**2N:4YR<K-D1UI4G6*2/:3(Z-S]W'0_C4?]MOMW_9OD55
M:3Y^5W=,>M0:A:1O/J#'()5#QV.:;J$0348K=&81W(19`,=%Z8IJ,62ZDU?4
ML76HSRPR>6AC6.=8_,#?>^8=J'U"6>]@5%,<7VAHR0WWL#N*8\2_8YQDX^V`
M_J*BB7&KF(,=D=SO`]R.:%%6!RE=7>YL06\D4A+SO(I&`K=O>K-)2UB=:5@H
..HHH&%%%%`!1110!__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>westlogo10152014.jpg
<TEXT>
begin 644 westlogo10152014.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!5`-(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_**^=_VB
M_P#@JM\"_P!E#XH3^#/'GC)M%\16UM%=R6HTN[N-L<H)0[HXV7D`\9S7"M_P
M7H_99123\2'`')_XD6H?_&:]6ED>8U8*I3H3<7JFHMI_@>75SO+J4W3J5X*2
MT:<DFOE<^PJ*R_!/C+3_`(B>#=)U_29FN-+UNSAU"SE:-HS+#*@=&VL`RY5@
M<$`CO7S%XO\`^"WO[,W@7Q=JNAZC\11'J.BWDMA=I'H]]*B31.4=0ZPE6`92
M,J2#C@US8;+L5B).&'IRDUNDF[>MCHQ.8X7#Q4Z]2,4]FVE?TN?6-%?-7P+_
M`."NOP!_:2^*VD^"?!OC:35_$NN-(MG:?V3>0^:8XWE?YWB51A$8\D=*]K^-
MOQK\,_LZ_"W6?&GC#4TT?PWH$(GOKMHWD$2E@@PJ`LQ+,H``))(HKY?BJ-54
M*U.49RV333=]%9=;O0*&886M2=:C4C*,=VFFE;5W?H=517Q]_P`/YOV6O^BD
M/_X(M0_^,UZQ^RI_P4&^%'[:^J:S:?#;Q'/XAE\/Q12WY_LVYMDMQ*6$8+2Q
MJ"3L;@$G"FM\1DN84*;JUJ$XQ6[<6DOFT8T,YP%::I4:\)2>R4DW]R9[3111
M7F'I!1110`4444`%%%%`!17*?%/X[^"?@;:6=QXT\7>&O"4&H2-%:R:QJ4-D
MMRZC+*AD8;B`02!TKC/^'@7P*_Z+)\+_`/PI[+_XY713PE>I'FA!M>2;.>IC
M*%.7+4FD^S:1Z]17._#+XO>%?C3X??5O!_B30_%.EQS-;->:5?1WD"RJ`60O
M&2NX!E)&<C(KHJQG"46XR5FC:$XR2E%W3"BBJ'B?Q-8^#M"NM2U*XCM;*SC,
MDLCG@`=AZDG@`<DD`<U)1G_$_P")NC?![P+J/B/7[M;/2],B\R5\%F;LJ(HY
M9V.`%'))%?FL/^"C_C7Q'^V%HWCV\LM9LO!6G3-8#1TAD:*'3Y2%D=\##S\+
M(3V*!1QUO?M4?$?XZ?M:_$<77AGPUXPT7PMIC%-*M+2X6WDD'>>8JXS(PQ@=
M$'`YW$\!K?[.W[2XT:2]U"P^(+6<8R[2ZYD(/4CS^![]JM)=0/UTL[V+4;.*
MX@D66&=!)&ZG*NI&01[$&I<U\A_L(?$#QCXV_99U?P+JZ75OXN\+!8;8R7T?
MVB_L6<,`LBNQ5PH>'>2-N8SGG->I_LG>`/$G@B;5/[56^@L)47;'=''F3=2R
M1EF*!1E68GYR<C@"H`]IHHHH`_G>_P"#@+5!J/\`P5(\;(#D66G:5!]/]"C?
M'_C]?&4-B^J3QVL0W273K"@]68A0/S-?4_\`P6VU?^V?^"HWQ8?(/V>[L[?_
M`+XL;<5XQ^R3X+/Q'_:L^&6@!/,&L>*M,M64]U:[CW?IFOZ?R1JADU"3^S3B
M_P#R5,_E_.HNOG5:*^U4DO\`R:Q_1O\`M6_&.#]AK_@GYXB\2!EBF\&>%TL]
M.4G&Z[\I+>V7\963\,U_,1-/+=3/+/(TTTK%Y)&.6=B<EC[DDFOV6_X.?OVC
MO[%^&7@'X4V=P!/X@O'\0:G&O!%O;YC@4^S2NY^L%?C1M.W.#C.,U\UX<9>Z
M67RQ<_BJRO\`):+\;L^E\2,P]KF$<'#X:4;?-ZO\+(^TO^#??0_[8_X*A>#Y
MBNY=-TO5+H_[/^BO&#^<@K[O_P"#FOX^_P#"%?LK>$_A_:S!;OQUK/VJZ16Y
M-I9J'((]#-)!_P!\&OD7_@VH\/'5O^"@FK7NW<NE>#KV0GT+W%J@/ZG\ZYK_
M`(.$/C__`,+E_P""ANIZ);SB;3?AWIMOH404_+Y[#[1<'Z[Y50_]<O:N?&X/
MZYQ?3OM2@I/Y-V_%HZ,%C/J?"%2VCJS<5\[7_!,^'"<"OZ#_`/@W_P#V7O\`
MAGW]@;2M<OK;R==^)5P?$-R67#K;,-EHA]O)42#WF-?AM^R)^S_>?M4?M->"
M/A[9*^[Q1JL5K<2("3!;`[[B3_@,*R-^%?NQ_P`%"_\`@KG\.?\`@F?HMCX*
MTC35\4^-;:QBCL_#MG,(8-)MP@6%KF7!\I=H&U`"[`9P`0U/Q`JXC%*EE&#B
MY3F^9I=EHK]$K]7V)\/J6'POM<WQDE&$/=3?=[V[NW1=S[2)`HSQ7\]WQ5_X
M.%/VE?B'J4TFEZ_X>\&6<A^2VTG1HI#&.P\RX$K$^_'TKEO#W_!=']J7P_J"
MSGXG/J`7K#>:+821M[$"%3^1KY"'AGFKCS.4$^UW^D;'V$_$W*8SY5&;7>R_
M^2N?T=45^;G_``28_P""Z,W[87Q'M/AI\2])TO1/&6H1.VDZGIVZ.RU=D4LT
M+1L28IMH9AABK[2!M.`?NC]HW]I'P?\`LI?"/5/&_C?6(='T'2E&]V4O+<2-
M]R&)!S)*YX"CW)P`2/D,PR3&8+%+!UX>^[62UO?:UM[GV&7YW@\;A?KE"?N+
M=O2UM[]K'=YQ1D`=:_#S]IS_`(.7OB=XXURXM_A;X>T7P/HB,1!=ZG`-1U.9
M>S,"?)CSUVA7Q_>-?/\`-_P6_P#VI9KLS?\`"U[U,MNV+H^GA![8\CI7U6&\
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M6OWGA[+I8#+J6$EO%:V[O5_BS\$XBS*./S*KBH?#)Z>BT7X(_H]_X(>_"`?!
M_P#X)G?#>)HO*NO$-O-K]P"N"QNIFD0G_MEY0_"OK2OR]_X(6_\`!2/XI?M=
M_$J3X>ZOI7@[3O`WP^\)Q"-M.L9HK@-&T5O;1EFE9>5$A/RC.SC%?IUJNJVV
MAZ9<7EY<0VMK:1----,X2.)%&69B>``!DDU_/?$^$Q%#,ZJQ-N:3<M'?XG=?
M@?T-PQBZ&(RVD\-?EBE'56^%6?XD/B;Q-8>#?#]YJNJW=O8:;I\+3W-Q.X2.
M&-1DL3Z`5^9G[;W[0%]^VAXL73-,\:^`M$\!Z9-NL;2]USR9-0D'`N9UV'!_
MNH?N#GJ3BU^W+^VSX<_:OU;_`(1RQ\9ZKX?\$:?+EDBT![@ZO*IXF<B53Y8/
M*)C_`&CS@#Q?1?A?\&;L#[;\7]?M2>R^"IF'?OYQ]J\.,>K/?)]!_8O&M%2/
MBK\%;8'^_P")L$?AY8]J[C1_^"<U[JMN8_\`A=WPD\F48:.+7WE##T*\`BLS
M1O@+^SI>8%S\==<C)]?"TL7\U:NLT7]ES]E2XV_:?CCJ,N>H:W2W_P#0H#5-
M@9?PR\$77_!.[]I_0M;F\=>`M1TW8%O197[[KVQE.V;Y%1AN1EW`%LEHU]:_
M532]1M]8TVWO+26.>UNXUFAEC.5D1AE6![@@@_C7Y6_'W]F[]G7P7\-X]2\&
M_%>]O]0CND26!/)U*66-@1Q"ODD8.TELG`[<U]6_\$JOVA]+^('PDE\"QZS=
M:MJ7@E0L,MU:?99)K%R?*PN]\^6<H3G@;*B7<#ZLHHHJ0/YE/^"LFJ?VQ_P4
MH^-$V<[/$LL&<_\`/-$C_P#9:UO^"-7@P^.?^"G'PBM@NY;+59-2;C.!;VTT
MP/YH*XG_`(**ZG_;/[??QIN0<B3QKJJC_@-RZ_TKM/\`@EO\3T_9\^*WQ`^)
MK2"*X\`>`-6O-/8_Q7]P8;*U7\9;D?@#7],UH361>SI_$Z2BO5Q45^+/YEHS
MA+/O:S^%5')^BE=_@A__``6(_:-_X::_X*%>/]6@N!/I&@70\.:85.5\FTS&
MS+[--YS_`/`ZXW]HWX.#X,?LX_`[[3"8=7\<:1J'BZY#+AA!/=+;VH/L8;8.
M/^NIK@?@=\)M3_:'^-WA7P78/)-JGC#5[?31*3E@9I`'E)_V5+.3Z`U]A_\`
M!PS;V/AC]MCPSX1TI!#I7@GP)I>DV<(/$,:O.57_`+Y*TH.&%Q&$RNCM&+;]
M(QY5][E?Y%3C+%8;%YI67Q227K)\S^Y*WS.W_P"#;37+'X=_%CXU^-M4;R]-
M\*>"1<74G]R(3&9__';<_E7Y[_%/XCW_`,8OB=XC\6ZH[2:CXGU.YU6Y+')W
MSRM(1^&['X5]!_LM_%A?@I_P3C_:-GAD\K5/'][H/@ZS(.&,;_:[BZQ[>1&5
M/_705\O8..%+'LH')/H*TR[!VS+%8QK5N,5Z1BF_Q?X&698R^6X3!QZ*4GZN
M32_!?B??/_!'1K/]E3X.?&K]J+6;2*X7P%I7_".^&8IA\MWJMT4R!]-T"MCG
M;,_I7PYX\\=ZQ\4/&VK>)/$.H7&K:[KMW)?7]Y.VZ2XF=BS,?Q/`Z```<"OT
M%_X*B>"&_8J_X)@?L\_`X;;?6?$$T_B_Q-&HPSW0C!VOZ[9+DH/^O=?2OSDZ
MFLL@Y<3.MF>_M)-1?]R'NJWJTY?,TX@<L-"CE>WLXIR7]^:YG]RLOD?<'_!$
MS_@F7X?_`."@WQ+\5ZAXWEU)?!?@NW@66WLI_(DU"[G+^7&9`,JBI&[-MP22
M@R!FO'/^"GW[.OA7]D_]N+QOX!\%3WDWAW0WM3;K=3>=+;M+:Q3/$7P"P5G(
M!/.,9SUJ#]DS_@I)\7?V(/"VK:-\-M>T_1;'6[L7UZ)M)MKMYI0@0'=*C$`*
M.@XZ^M>7?&+XN:_\>OBAKGC+Q3>C4?$/B.Z:\O[D1+$LLA`'"*`J@````8`%
M:8;!YBLVJXFM47L'&T8IO?35JUK[ZWZV,\5C<M>44L+1IOVZE>4FEMKHG?;;
MIT.S_8+U.\T;]N#X/W.GLRWD?C+2A%M."=UW&I'T*DCZ&OK/_@XS_:NOOBY^
MV-'\.+6[<>&_AI;1JT"-\DVHW$:RRRL.Y2-XXQGI\^/O&O$O^",_PQ?XJ_\`
M!3'X4V:INBTG4GUN8D9"K:0R3`G_`(&J#\:T_P#@MI\$?$/P<_X*-?$&[UJT
MN(['QE>_VYH]VRGRKVWD1`0C="8W#(PZC:.Q&>.NL/4XCI*=N:%)M>KE;\%?
M[SMP[Q%/ARK*%^6=1)^BC?\`%V^X^8?!6C6?B/QIH^G:CJ,.CZ?J%]!;76H3
M*6CL(GD57F8#J$4EB/\`9K]9OVX?^""?@/1_V1=.U[]G[3O$_C;QF+FU\F6#
M68KR#6;5R1+,=Q6(`#Y@8R!VP0:_(:O6/V:/VYOBS^Q_J"R_#SQQK.@VN_S)
M-.\P7&G3GOOMI`T9)]0H/O7;G6`Q]:=.M@*W(X._*[\LO*5M?S.'(\PR^A"I
M1Q]'G4U;F5N:/I?3\CT'_AS=^T]G_DCGB3_P)L__`(]7W9X@_P""/_CWXV?\
M$OO@WX>\8>++?X:R_"FTUS6-8T[4-/-_*K37#RH"8Y@JA(5)P"W^L/TKNO\`
M@EQ_P7R'[4GQ-TGX;?%#1--T'Q7K;>1I.L::66PU*?&1!)$Y+0R-@[2&96;Y
M<*2,_2G_``61^+I^#'_!-CXJ:C'/Y%WJ>E#1+8@X9GO)%MR!_P``D<_@:_.L
MWX@SQX^A@,13C3GSIQ:5[WO&ZNVFK2?2Z/TC*.'\C6`KX[#5)5(.#4DW;:TK
M.R3O=(_FK5Q(H9<[6Y&1CBO5OV)_V5-2_;7_`&F/#?PVTK4(M(N=?,[/?RP&
M>.SCAA>9W9`5+<)MQD<L*\J`"C`Z#@5^E7_!L9\)1XH_:W\:^,)HB\/A+PZ+
M2%^R3W<R@?CY<$@_X%7Z9Q!F$L#EM;%0=G&.GJ]%^+1^7\/9?''9E1PTU>,I
M:^BU?X(^_/\`@E#_`,$M3_P3'TOQW<ZKXNT_Q5>>*GM6-W%8&Q2RM[=93M.Z
M1\Y:1F)R`,"O'_V]/^"B>@_'+4;OP3I46O7/@FTFQ=7FF7\=J=<=3T^>)SY"
ML,CD;R,D8`K[%_;\\*:YXO\`V5O%$.@1K=75K"+N>Q8R!=2MXSNE@)C96^9,
MG`/S%0IR":_*?0_CQX=T=%\[X6_#J_7@CSVU`$_^37]*_FO&XZOC<1+$XE\T
MY6N]%LK=--D?TU@,!0P5".&PT;0CLM]W?KYFEHOB3X*Q8^W^$/B9,>YB\1V8
M7\OLP/ZUU.C>-OV9X'!O?`OQ3;'7.N0N/T9*SM&_:\\&Z85\SX%?"F;''WKD
MD_\`?;M7<^&OV^O!.F;=O[.7P\E]X$!_]"@:N;8["UH/Q0_8[AV_:_`GQ`!Z
M$RWC2#_QVY'\J[#1/C'^Q-D#_A"-65AQFXM+N;^4S5;\,_\`!1SPLNWR/V9[
M;V-C9Q'\L6O]:]$\+_\`!1&SN=@MOV<_'<?_`%YZ.CXZ=/W:U#`\T^,?Q,_9
M(U7X-:W'X=\)2_VL8T-NEEIL]A>%A(APES)&Z1\9R6SD9'4UXC^SG^TMX/\`
MV<?CCH_BK0M`\5V=O`QMK]+G7(;A9+63`D!1;9=VT8<#(^9!S7TQ^V+_`,%!
M+.Y^"/\`9&I?!O7[!-;N8XUMO&&GM::?=+&1(P!CD61G4A2`,#U]_E?X=7\O
M[1_Q!L?#'A+X2_#\:IJ+846ZWXCMD'WI9&-R0L:CDG'H!DD"A+0#]DM*U2WU
MO3+:]M)DN;2[B6:&5#E948`JP/<$$&BO$/!W[$__``C/A'2M-/C/Q+"=/LX;
M;R[2YDCMTV(%Q&I<E4&.`22!CDT5('\X_P"UMJ?]M_M7_%&]SG[7XOU>;_OJ
M]F/]:Y#3/%=[H_AW5=+MY/+M-;\A;L#K(L+F1%^F_#?5%]*M_%'5AK_Q0\37
MX((O]7O+G(.<[YW;^M85?UG0I)480?1+\#^2<35;KSG%[M_B?H=_P;<_LZGX
MH?MIZIXYNH!)IOPWTAY8G9<J+Z[W0Q?B(A<'V(%>9_\`!>CQ,/$O_!4?XA*K
M;DTRWTVQ'MMLH6(_[Z<U^H?_``;V?LX_\*3_`."?NG^(+JW$6K_$F]EUZ4E<
M/]F_U-JI]O+C\P?]=C7X]_\`!5GQ%_PE'_!2+XT76[>$\3SVH/M"J0_^TZ^`
MR;&_7>*<353O&G#D7RDK_C<_0,ZP7U'A;#TGI*I/G?S3M^%CQ%O%UZ?!:Z`)
M"--6_.I&,?QS&)8@Q^B@@?[QKZ'_`."07[+H_:P_;Z\$:)=6WVG0M"G/B+6`
M5RGV>U*NJ-[/,88_HYKYEK]L_P#@V9_9?_X0?X`^*?BK?V^V^\<WW]F::[J<
MBPM20[*?1YRX/_7!:^@XNS)9?E56K#24O=7K+K\E=_(^>X0RUYCFM*G/6,?>
M?I'I\W9?,^5?^#E;QQ+XC_;^TG2&)\GPYX3M(T7MNFFGE8_B-@_X#7YZ2OY<
M;-UVC-?I!_P<P_!74_"7[9/AWQRT$K:'XOT"*RCN-I\M+JU>0/$3T!\N2-@.
MX+>AK\X'7>A&<9K3A&5-Y/A_9[<J^_K^-R.+XSCG.(]I_-^'3\#][O!?[!'[
M.G[*7_!.'0O'OQ-^%7AG7KWPQX0M=5UZZDL$EOKVX:%'=07909&D?8N2!G`R
M*^5Q_P`%&?V`"/\`DV+51_W`K#_Y*KY[_;'_`."TGQ,_;+_9NTKX8ZII6A:!
MHT`M_P"UKC3FE,VMM`%,88,=L:;U5RBYRRCD`8KY1\&^#=6^(OB[3=!T'3;S
M6-;UBX6UL;&UC,D]U*QPJ*HZG/X`<G`%>!E'"V(=.I6S>K-2<F[1J-)1^3MW
M]$?09MQ7156G0RBE!Q44M::;<OFK_P#!/W/_`&!OVH/V29?`OCGXU>#/A;'\
M)-'^'0AT[4]?O=(CCD(NBH\J(6[RLW/E!@!GYU]ZV/VB_P#@I?\`L-?M9^`7
M\-?$'Q=HGB726)>-;G1-1$MHY&/,AE6$/$_^TA!_"O-_VBO^"?&H?LC?\$`?
M%O@2UC6\\40);^)_$SVPWB:<7<$MP%(^\D,,84'NL.[O7XF[O0Y%>-DO#>`S
M:K5QM.M47)-QBU+6R2L[M-ZMMH]G.^)<?E%*E@ZE&F^>"E)..EVW=632T229
M^E^N?\$,O!7[6GP\U'Q[^RK\45\3Z!;7DMF-+\1VTUO^^C5':**Z,:$D!UQO
MCQSR_6OSF\>^!-7^%_CC5_#>OV,NF:YH-Y+87]I*07MIXV*NA()!P0>02#U%
M?5G[!O\`P6=^(/[`7P)UCP'X=\.^&=<L;Z]EU&QN=1,JR:=/*BJYPA`E3*!@
MIP<YYP<#Y1\;>,M4^(WC+5O$.MWDNH:QKEY+J%]=2?>N)Y7+NY[<L3QVK[C)
M:&:4:]6EC)<U)?`W;F:\[6_%7N?"YW7RJM0I5<%'EJOXTK\J]+W_``=CMOV,
M='U#7_VP?A39Z47&HS^+]*%N4^\K"[B.1]`"?PK]:O\`@Z`^+9\/_LT?#_P5
M'*%E\3^(7U&9`>6AM(2/R\RXC/U6OG__`(-W_P#@GQJWQ#^-5O\`''Q'ITUM
MX3\)>8GAXSQE1JVH,IC,T8/6*%6?YNAD*@9V-BG_`,'/7B^ZU/\`;(\#:(^X
M6>D>$1<P@]#)/=S!R/PAC'X5\UCL11QW%.'H4W?V*;?KV^6GXGTV!P];`<*X
MBO45G6:2]._SU/S7K]R/^#8_X3?\(M^QYXN\72)MF\7^)7BC/=H+2)8U_P#(
MCS5^&]?<_P#P1!_:)^+E[^UQ\._A)X<\;:QIO@"ZU6?5]3TF-8GADABB>>9=
MS(719"BJ0K#);U->YQM@:N*RFI"G)12]YWOM'6VE]=$>%P/CJ6%S:G.I%R<O
M=5N\M/N/Z"&0.I!&0>H]:_++]M/P]X[_`&7OVD-3TWPY;6\_A_5_^)GHXC\-
M6=V(HG;#PY\ACF-P5&3G:5/>OU-48&*\!_X*-_`;5?C5^S_<7'AJ>_M_%'AA
MSJ5@+2Y:![E0,30Y##[R<C/\2+7\X)ZG])'P=X9_:=_:`M%46'A^>9>,;/`%
MO@_BEL/YUWWAO]K/]JV)E-KX&O;@=O\`BB7C!_%0M>/^$?#7QSU%(VTKQ!XE
M16`*X\9Q1#'&.#<CVKT?PS\)/VL;M!]B\5>(D7L'\<VS#\OM#5H[`>HZ+^UO
M^UXY4-\)XKD?]-M$E@)_.<8_*NQT3]IW]K"\"^9\$="?U+W/V<_^/3FO-=#^
M!O[9K8:/QE/&B]Y_$%M,,>_RM7'>,_B'^U#%K!\'P^-8O%$VLQ&V_P")'?V$
M[-O!#(LBA9%8`'<R@;1DYXJ;`-^-W[3OQT_:7^,.F>%K3PK'HFH0RMIL>G1Z
M7'>6[3ASYDQGN(F"J`!EE.T*F>:^\OV5/V:+;]GKP-''>SVFL>*KY`VJZM'9
M0VYF;KY48C1<0J?N@\GDGD\8G[$O[)3_`+-'@02:UJU[K_C#58U.IWMQ=23I
M".HMX=Y.(U/4]6(R>,`>WU+8!1112`_-M_\`@V'^"DCEF\:_%(LQR2;VQ))]
M?^/:F2?\&P7P3="/^$T^*0R,<7MCQ_Y+5^D]%?2?ZX9S_P!!$OP_R/FO]3\F
M_P"@>/X_YF1X!\$:?\-/`NC>'=(A^SZ7H-C#IUG%_P`\X8HUC1?P517P?\5O
M^#<OX1?&+XI>)?%VJ^,OB7'J7BC5+G5KI(;NS$223RM(RH#;DA06(&23@#DU
M^@]%>9@<WQF#G*IA:CBY;M=3T\=E&#QD(T\334E'9/H?FRW_``;"?!,J<>-?
MBD#Z_;+'C_R6K[W^`7P5T7]G+X+>&?`OAV*6+1?"NGQ:=:>:0TLBHN#(Y``+
MNV68@#+,>*Z^BM,PSO'XZ*ABZKFEJK]R,OR/`X&3GA*2@WH['!_M%_LS^"?V
MK_AA>^#_`![H5MK^A7I$GE2DI);2@';-%(N&CD7)PRD'DCD$@_G)\3O^#6WP
MIJFJSS^#_BMXAT6T=B8[35=+BU`QCL/-1XB<>ZDU^J]%7EG$&89>G'"57%/I
MHU]S31GF?#^7Y@U+%TE)KKJG]ZLS\D_!W_!K%IT-XC^(?C)J-S;@_/%IN@1P
M.P]GDF<#_ODU]R_L7?\`!+OX/?L)(UWX+\//-XBEC,4VOZK+]KU*1#U57("Q
M*>ZQJH/?-?0]%;9AQ1FF-@Z>)K-Q?162?K9*_P`S++N%\KP,_:8:BE+N[M_)
MMNWR(=0T^#5[">UNH(KFUN8VBFAE0/'*C##*RG@@@D$'@@U^<?[1/_!M-\*/
MBAXHN]5\$>)O$'PZ-Y(TK:?'#'J.G0L23B)'*R(O/"^80.@`'%?I%17'EN<8
MW`2<\'4<&][;/U3T9V9EE&#Q\%#&4U-+:^Z]&M3\@+?_`(-7;C[?B7XUQ_9<
M]4\,?O,?0W.*]Y_9O_X-Q?@C\'=:M]3\6WFO_$N\MF#I;ZFR6NG$CH6@BY?Z
M.[*>X-?H-17JXGC/.:\'3G7=GV2C^*29Y.%X,R;#S]I3H*Z[MO\`!MHJZ)H=
MEX:TJWL-.M+:PL;.-8;>VMXEBA@C485$10`J@<``8%?.?_!07_@EC\./^"BM
MOI5SXK?6-&\0Z%$]O8:SI4J).D+'<89%=622/=\P!&02<$9.?I:BO!PF,KX:
MLJ^'DXS75'OXK!4,31="O!2@^CV/RIF_X-9?"#2YC^+_`(J5,]&T>V9L>F=X
MY_"O?_\`@GM_P1*\%_\`!/[XU2^.]/\`%WB+Q3K+:9-ID*WT$$,%NLK(SR*$
M&[=A-O7HQK[7HKV<5Q9FV)I2H5ZS<9:-62O]R/&PO">4X:K&O1HI2CJG=Z?>
MPI&`92"`01T]:6BOG3Z(_)']N']C"P^"?[1>IP+K?AGP_H'B%VU/25OQ<+LC
M=OWD0\N%P`DA(`SG:4XYK@M*_9L\/7<)D;XP_"NS91G:\U\&_P#285^E/_!1
M[]F:V_:*^`D\RK.-8\*,VJ63V\(FGD15/G0JI90V]!P,CYD6OR_TKPS\/]7B
M@AM_$'C>?4[MTB@MH?#D,AF=N%1<7622<``#FM(O0#3@^!K7&M6NF:)\2_".
MMZA?3+;6MKIMSJ+RW+L<!%46XR2?\3Q7Z-?L`?\`!/[3?V4/#[:SK$=EJ'CS
M4X]MS=1#=%IT9_Y80$@'TW/@%CQT`JC_`,$__P#@GSIG[-ML/%6M;]2\7ZA%
MB'[3"J'1HF7F)55G`E.<.X8_W1QG/U&!BI<NP!1114@%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`$9%?./[/'_``3[\&?"
M#]H+Q?XWA7[==-J3G1[62$+#H:R1I))Y?)W,6D8!B!M7@#J2447`^CJ***`"
*BBB@`HHHH`__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
